Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Asahi Kasei to Mass-Produce iPS-Derived Regenerative Medicine Product

Filed Under: Industry Tagged With: , , , , ,

Asahi Kasei Corp. (TYO:3407) is starting to establish infrastructure for manufacturing regenerative medicine products. The company has invested several hundred…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Asahi Kasei Works on New iPS Treatments for Orthopedic Sector
Asahi Kasei Works on New iPS Treatments for Orthopedic…
Asahi Kasei Turns Focus to Next-Gen Technologies
Asahi Kasei Turns Focus to Next-Gen Technologies
Mitsubishi Chemical to Produce Regenerative Medicine Materials From Plants
Mitsubishi Chemical to Produce Regenerative Medicine…
Sekisui Chemical Moves Into Cell Culture Sector
Sekisui Chemical Moves Into Cell Culture Sector
U.S.–Japanese Research Team Creates Multi-Organ Structure From Human iPS Cells
U.S.–Japanese Research Team Creates Multi-Organ Structure…
Nissan Chemical Eyes Global Expansion of High-Performance, Cost-Effective Cell Culture Supplement
Nissan Chemical Eyes Global Expansion of High-Performance,…